Advances in the treatment of attention-deficit/hyperactivity disorder: A guide for pediatric neurologists

Seminars in Pediatric Neurology

Volumn 17, Issue 4, 2010, Pages 230-236

  Wigal, Sharon B ^a   Chae, Stephanie ^a   Patel, Avni ^a   Steinberg Epstein, Robin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; CENTRAL STIMULANT AGENT; GUANFACINE; INTUNIV; LISDEXAMFETAMINE; METHYLPHENIDATE; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANXIETY; ATTENTION DEFICIT DISORDER; CONSTIPATION; DECREASED APPETITE; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RELEASE; FAMILY HISTORY; HEADACHE; HEART RATE; HUMAN; INSOMNIA; IRRITABILITY; MEDICAL HISTORY; MINOR AFFECTIVE DISORDER; MORNING DOSAGE; NAUSEA; OSMOSIS; REVIEW; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; STOMACH PAIN; SWEAT GLAND DISEASE; SYSTOLIC BLOOD PRESSURE; TREATMENT FAILURE; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DEXTROAMPHETAMINE; GUANFACINE; HUMANS; METHYLPHENIDATE; PROPYLAMINES;

EID: 78650268510     PISSN: 10719091     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.spen.2010.10.005     Document Type: Review

References (23)

1. IV TR: Diagnostic and Statistical Manual of Mental Disorders 2000, 78-85. American Psychiatric Association, DSM, American Psychiatric Publishing, Inc, Washington, DC. (ed 4).
2. A 14-month Randomized Clinical Trial of Treatment strategies for attention deficit hyperactivity disorder. Arch Gen Psychiatry 1999, 56:1073-1086. MTA Cooperative Group.
3. Kutcher S., Aman M., Brooks S.J., et al. International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behavior disorders (DBDs): clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol 2004, 14:11-28.
4. Larzelere M.M., Campbell J.S., Robertson M. Complementary and alternative medicine usage for behavioral health indications. Prim Care 2010, 37:213-236.
5. Pliszka S.R., Crismon M.L., Hughes C.W., et al. Texas Consensus Conference Panel on pharmacotherapy of childhood attention deficit hyperactivity disorder. Revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006, 45:642-657.
6. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007, 7:894-921.
7. Elia J., Ambrosini P.J., Rapoport J.L. Treatment of attention-deficit-hyperactivity disorder. N Engl J Med 1999, 340:780-788.
8. Connor D.F., Doerflor L.A. Attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder or conduct disorder. Curr Attention Dis Rep 2009, 1:5-11.
9. Official action: Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007, 46:894-921. American Academy of Child and Adolescent Psychiatry (AACAP).
10. Poncin Y., Sukhodolsky D.G., McGuire J., et al. Drug and non-drug treatments of children with ADHD and tic disorders. Eur Child Adolesc Psychiatry 7 2007, 16(suppl 1):78-88.
11. Swanson J., Gupta S., Williams L., et al. Efficacy of a new pattern of delivery of methylphenidate for the treatment of ADHD: Effects on activity level in the classroom and on the playground. J Am Acad Child Adolesc Psychiatry 2002, 41:1306-1314.
12. Swanson J.M., Wigal S.B., Wigal T., et al. A comparison of once-daily extended release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (The Comacs Study). Pediatrics 2004, 113:206-216.
13. Wolraich M.L., Greenhill L.L., Pelham W., et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 2000, 108:883-892.
14. Biederman J., Boellner S.W., Childress A.C., et al. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: A double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry 2007, 62:970-976.
15. Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat 2010, 6:317-327.
16. Wigal S.B., Kollins S.H., Childress A.C., et al. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health 2009, 3:17.
17. Faraone S.V., Wigal S.B., Hodgkins P. Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with ADHD. J Atten Disord 2007, 11:74-82.
18. Wigal S.B., McGough J.J., McCracken J.T., et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord 2005, 9:275-289.
19. Michelson D., Allen A.J., Busner J., et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. Am J Psychiatry 2002, 159:1896-1901.
20. Greenhill L.L., Newcorn J.H., Gao H., et al. Effect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetine. J Am Acad Child Adolesc Psychiatry 2007, 46:566-572.
21. Biederman J., Melmed R.D., Patel A., et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2008, 121:e73-e84.
22. Connor D.F., Rubin J. Guanfacine extended release in the treatment of attention deficit hyperactivity disorder in children and adolescents. Drugs Today 2010, 46:299-314.
23. Spencer T.J., Greenbaum M., Ginsberg L.D., et al. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009, 19:501-510.